Maintenance obinutuzumab for central nervous system lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a maintenance drug called obinutuzumab can help prevent relapse in people with primary central nervous system lymphoma (a rare lymphoma in the brain or spine) who have already responded to initial chemotherapy. It is for those who have achieved at least a partial or complete response to their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma (CD20+ B-cell) that started in the brain or spinal fluid, confirmed by biopsy or spinal tap.
- You have already completed your first round of high-dose methotrexate chemotherapy (with or without brain radiation) and your scans show the tumor shrunk or disappeared.
- Your most recent brain MRI must be within the last 30 days and show a response to treatment.
- You are within 75 days of finishing your initial treatment and are able to start the study drug.
- You have a good level of daily function (Karnofsky score 60 or higher, ECOG 0-2).
- Your kidney, liver, and blood counts meet minimum safety levels (e.g., creatinine clearance >30, platelets ≤75,000).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests whether taking the drug tirabrutinib (a pill) can help keep primary CNS lymphoma from coming back after successful initial chemotherapy. It compares the drug to a placebo (a dummy pill).
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.